TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

PURPOSE: This phase 1 dose-escalation portion of the study evaluated the safety, pharmacokinetics (PK), and antitumor activity of TAK-264 in Asian patients with advanced gastrointestinal (GI) carcinoma or metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma expressing guanylyl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Res Treat
Autors principals: Bang, Yung-Jue, Takano, Toshimi, Lin, Chia-Chi, Fasanmade, Adedigbo, Yang, Huyuan, Danaee, Hadi, Asato, Takayuki, Kalebic, Thea, Wang, Hui, Doi, Toshihiko
Format: Artigo
Idioma:Inglês
Publicat: Korean Cancer Association 2018
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5912138/
https://ncbi.nlm.nih.gov/pubmed/28494535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2017.074
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars